KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Weighted Average and Diluted) (2016 - 2025)

Jazz Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $3.34 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 10.6% to $3.34 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 through Dec 2025, down 114.94% year-over-year, with the annual reading at -$5.84 for FY2025, 167.51% down from the prior year.
  • EPS (Weighted Average and Diluted) was $3.34 for Q4 2025 at Jazz Pharmaceuticals, down from $4.08 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $4.08 in Q3 2025 and troughed at -$11.74 in Q2 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is $1.04 (2023), against an average of $0.08.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 611.11% in 2022 and later soared 3366.67% in 2023.
  • Tracing JAZZ's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.54 in 2021, then crashed by 611.11% to -$3.84 in 2022, then surged by 137.24% to $1.43 in 2023, then soared by 111.19% to $3.02 in 2024, then grew by 10.6% to $3.34 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $3.34, $4.08, and -$11.74 for Q4 2025, Q3 2025, and Q2 2025 respectively.